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Mary-Margaret Chren1,2, Eleni Linos1, Jeanette S. Torres2,5, Sarah E. Stuart1, Rupa Parvataneni1 and
W. John Boscardin3,4
For most cutaneous basal cell and squamous cell carcinomas (nonmelanoma skin cancers (NMSCs)),
data are insufficient to permit evidence-based choices among treatments. To compare tumor recurrence
after treatments, we conducted a prospective cohort study of consecutive patients with primary NMSCs
treated with the most common treatments, in two practices in 1999–2000. Recurrence was determined from
medical records by observers blinded to treatment type. Follow-up was available for 1,174 patients with 1,488
tumors (93.8%) at median 7.4 years; of these tumors, 24.3% (N¼ 361) were treated with destruction with
electrodessication/curettage, 38.3% (N¼ 571) with excision, and 37.4% (N¼ 556) with histologically guided serial
excision (Mohs surgery). The overall 5-year tumor recurrence rate (95% confidence interval) was 3.3% (2.3, 4.4).
Unadjusted recurrence rates did not differ after treatments: 4.9% (2.3, 7.4) after destruction, 3.5% (1.8, 5.2) after
excision, and 2.1% (0.6, 3.5) after Mohs surgery (P¼ 0.26), and no difference was seen after adjustment for risk
factors. In tumors treated only with excision or Mohs surgery, the hazard of recurrence was not significantly
different, even after adjustment for propensity for treatment with Mohs surgery. These data indicate that
common treatments for NMSCs were at least 95% effective, and further studies are needed to guide therapeutic
choices for different clinical subgroups.
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INTRODUCTION
Cutaneous basal cell carcinomas (BCCs) and squamous cell
carcinomas (SCCs)—also called nonmelanoma skin cancers
(NMSCs)—are the most common malignancies (Rogers et al.,
2010). Typically, NMSCs affect quality of life but not survival,
and the primary goal of treatment is the prevention of
recurrence, as recurrent tumors are more difficult to treat.
The most common treatments for primary NMSCs are tumor
destruction with electrodessication and curettage, simple
excision, and histologically guided serial excision called
Mohs surgery. For primary tumors, existing data are
insufficient to permit evidence-based choices among
therapies (Bath-Hextall et al., 2004), which vary in cost
(Essers et al., 2006; Otley, 2006; Wilson et al., 2012).
Substantial unexplained variations exist in treatment choices
(Chren et al., 2004), and the dearth of data has resulted in
‘‘competing camps’’ for different treatments (Williford and
Feldman, 2004).
A randomized controlled trial of treatments for facial BCCs
determined that 5-year recurrence rates after excision (4.1%)
and Mohs surgery (2.5%) were similar (P¼ 0.40; Mosterd
et al., 2008). However, these results have been controversial
(Williford and Feldman, 2004; Otley, 2005; Feldman et al.,
2008). We found similar recurrence rates in 495 patients
treated at a Veterans Affairs Medical Center (VA; Chren et al.,
2011), who were part of a larger prospective cohort study of
patients treated at two hospitals. These results were reported
first, because follow-up from the electronic medical records
at VA was complete sooner than at the other site. However,
the sample size was too small to permit comparisons of
effectiveness among treatments.
We now report complete follow-up on the entire cohort
from the two hospitals. Our goal was to compare the
effectiveness of the most common treatments for preventing
recurrence of NMSC.
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RESULTS
Patient, tumor, and care characteristics
The study enrolled 1,253 eligible patients, with 1,585 primary
NMSCs treated with destruction, excision, or Mohs surgery.
Follow-up information was available for 1,174 patients
(93.7%) with 1,488 tumors (93.8%; Figure 1). Patients lost to
follow-up were similar to those with follow-up in most
features, but were more likely to be female (38 vs. 26%), to
have worse mental health status (median Short Form-12
Mental Component Score 41.2 vs. 51.5), and to have BCC
rather than SCC (89 vs. 75%).
Patients, tumors, and care differed in the treatment groups
(Table 1). For example, tumors treated with destruction were
much less likely to be located in the H-zone of the face, and
much less likely to have histological risk factors for recurrence
(NCCN, 2011). Tumors treated with Mohs surgery were smaller
and much more likely to be located in the H-zone of the face.
Size of excisional margins was available for 289 tumors
(50.6% of excised tumors); the median margin size was
3.0 mm (interquartile range 3.0–4.0). Tumor remained at the
margins of the excised specimen for 29 tumors (5.1%). Of
these tumors, 2 were retreated with destruction, 11 with
additional excisions, 7 with Mohs surgery, and 9 tumors were
not retreated.
Follow-up
The overall median follow-up time after treatment was 7.4
years (3.0–8.8); follow-up duration did not differ (P¼0.16)
among treatment groups. Six hundred and fifty-two patients
were alive in December 2011 (median follow-up time, 8.5
(7.3, 9.2) years) and 522 patients had died (median follow-up
time, 3.9 (1.6, 7.0) years).
Three hundred and twenty-eight patients (41.6% of those
alive) with 396 tumors (40.4%) consented to examinations by
the study dermatologist. Examined patients and tumors
were similar (all P-values40.1) to those not examined in
almost all features, but examined patients had better
mental health status (median Mental Component Scores 53.7
vs. 50.0, P¼0.002). Recurrence was suspected in 35
(9%) examined tumor locations. On the basis of a subsequent
medical record review, 24 tumors were determined not to be
recurrent, 8 were verified to be recurrent, and none to be
probably recurrent, and for 3 tumors recurrence was uncertain
(for these tumors, the study dermatologist had judged the
likelihood of recurrence as o20% for 2 tumors and 21–40%
for 1 tumor).
Tumor recurrence
Fifty tumors recurred and three tumors probably recurred.
Overall, the unadjusted 5-year recurrence rate was 3.3% (95%
confidence interval 2.3, 4.4). Unadjusted 5-year recurrence
rates did not differ significantly (P¼0.26) among treatments:
4.9% (2.3, 7.4) after destruction, 3.5% (1.8, 5.2) after excision,
and 2.1% (0.6, 3.5) after Mohs surgery.
The median time of detection of recurrence was 3.9 years
(1.8–5.3) and did not differ (P40.11) at the two clinical sites
or among treatment groups. Figure 2 depicts the cumulative
incidence of recurrence in the treatment groups.
The median surgical margin size for excised tumors
that recurred was 3.0 mm (3.0–3.0) and for excised tumors
that did not recur was 3.0 mm (interquartile range 3.0–4.0).
One of the recurrences occurred after an incomplete excision;
this tumor had been subsequently treated with a second
excision.
Table 2 reports 5-year recurrence rates in clinical sub-
groups. Few characteristics were significantly related to tumor
recurrence, including characteristics conventionally consid-
ered high risk (NCCN, 2011). Overall, tumors in patients with
1,536 Patients with 1,993 NMSCs
diagnosed in 1999–2000
Excluded:
153 Recurrent tumors
24 tumors in patients with basal cell
nevus syndrome
231 Tumors not treated with destruction,
excision, or Mohs surgery
1,253 Patients with 1,585 NMSCs
enrolled in study
University site
738 Patients with
946 tumors
VA site
515 Patients with
639 tumors
Lost to follow-up
8 Patients (with 8 tumors)
507 Patients with 631 tumors667 Patients with 857 tumors
132 Treated with destruction229 Treated with destruction
381 Treated with Mohs surgery
1,174 Patients with 1,488 NMSCs
in final analytic cohort
247 Treated with excision 324 Treated with excision
175 Treated with Mohs surgery
not seen after treatment
Lost to follow-up
71 Patients (with 89 tumors)
not seen after treatment
Figure 1. Flow diagram. Derivation of analytic cohort from consecutive patients diagnosed with nonmelanoma skin cancer (NMSC) during 1999–2000.
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a history of HIV, in those with multiple NMSCs at
presentation, and in those who visited dermatology more
often were more likely (Po0.01) to recur.
Table 3 contains 5-year recurrence rates after each treat-
ment, in subgroups conventionally considered high risk
(NCCN, 2011). There were few differences in the recurrence
rates; at the university site, recurrence was less likely after
Mohs surgery for tumors located in the H-zone of the face
(P¼ 0.05), and was somewhat more likely after destruction for
invasive tumors (P¼0.04).
The final Cox proportional hazard model adjusted
for a history of HIV infection, multiple NMSCs at presen-
tation, tumor location in the H-zone of the face, histological
subtype and invasiveness, and 42 annual dermatology visits
during the follow-up period; for analyses of the entire sample,
clinical site was also included. Adjusted 5-year recurrence
Table 1. Characteristics of 1,174 patients with 1,488 NMSCs treated with destruction, excision, or Mohs surgery1,2
Treatment group
University site VA site
Characteristic Destruction Excision Mohs surgery P-value Destruction Excision Mohs surgery P-value
Patient characteristics n¼144 n¼203 n¼320 n¼92 n¼ 268 n¼ 147
Age, years, median (IQR) 60 (49–72) 61 (51–75) 68 (52–77) 0.003 75 (64–80) 75 (65–80) 72 (63–78) 0.14
Gender male 66% 56% 53% 0.04 100% 96% 97% 0.12
Skin type I or II
(Fitzpatrick, 1988; never
tans or tans a little)
45% 49% 43% 0.63 35% 30% 40% 0.20
Health status (SF-12; Ware
et al., 1996)
Physical Component
Score, median (IQR)
52.6 (42.0–56.5) 52.6 (46.6–55.9) 53.1 (43.5–56.5) 0.97 43.4 (30.2–52.8) 42.7 (32.1–53.1) 40.3 (34.3–51.2) 0.93
Mental Component
Score, median (IQR)
52.5 (45.8–57.8) 52.4 (42.9–57.0) 51.6 (41.5–57.2) 0.68 49.2 (40.4–57.9) 51.5 (37.9–57.7) 50.4 (41.2–58.0) 0.75
Comorbidity (Charlson
index; Katz et al., 1996),
median (IQR)
0.0 (0.0–2.5) 1.0 (0.0–2.5) 1.0 (0.0–2.0) 0.92 2.0 (1.0–4.0) 1.0 (0.8–3.0) 1.0 (0.0–6.0) 0.78
History of prior NMSC 57% 43% 48% 0.04 55% 58% 48% 0.17
History of organ
transplantation
1% 4% 4% 0.27 1% 2% 3% 0.43
History of HIV 8% 4% 2% 0.04 1% 1% 1% 0.96
Number of NMSCs at
presentation, mean±SD
1.4±0.8 1.2±0.6 1.4±0.9 0.01 1.2±0.5 1.2±0.6 1.4±1.0 0.41
Tumor characteristics n¼229 n¼247 n¼381 n¼132 n¼ 324 n¼ 175
Histological type, BCC 81% 74% 78% o0.001 86% 65% 75% o0.001
Histopathological risk
factor for recurrence
(NCCN, 2011)
7% 27% 32% o0.001 2% 21% 18% o0.001
Tumor diameter, mm,
median (IQR)
9.0 (6.0–12.0) 8.0 (5.2–12.0) 8.0 (5.0–11.0) 0.04 8.0 (5.0–14.2) 10.0 (6.0–15.0) 7.0 (5.0–10.5) o0.001
Tumor present in the
‘‘H-zone’’ of the face
6% 14% 58% o0.001 18% 35% 79% o0.001
Care characteristics
Training level of treating
clinician
Attending physician 91% 90% 98% o0.001 4% 9% 97% o0.001
Resident physician 9% 10% 2% 75% 90% 3%
Nurse practitioner N.A. N.A. N.A. 20% 1% 0%
Annual visits to
dermatology over follow-
up period, median (IQR)
1.5 (0.5–2.4) 0.9 (0.3–2.2) 1.1 (0.4–2.6) 0.02 1.9 (1–3.1) 2.1 (1.1–3.3) 2.0 (0.8–3.0) 0.62
Abbreviations: BCC, basal cell carcinoma; IQR, interquartile range; N.A., not applicable; NMSC, nonmelanoma skin cancer; SF-12, Short Form-12; VA,
Veterans Affairs Medical Center.
1Data were missing at the university site/VA site for the following number of patients or tumors: skin type 300/158, health status 319/187, comorbidity 297/147,
tumor diameter 110/103, H-zone 0/1, and training level of clinician 11/25.
2P-value refers to comparison among the treatment groups.
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rates were 2.8% (1.8, 3.8) overall, 3.8% (1.4, 6.1) after
destruction, 3.3% (1.6, 4.9) after excision, and 1.7% (0.4, 3.0)
after Mohs surgery (P¼ 0.26; Supplementary Table S1 online).
Comparison of recurrence rates after excision or Mohs surgery
The difference in recurrence rates between excision and
Mohs surgery was 1.6% (0.1, 3.0). There was no statisti-
cally significant difference in the hazard of tumor recurrence
after Mohs surgery compared with excision in any of the
adjusted models (by site, in the overall sample, and in
propensity-matched pairs), which are described in Table 4.
DISCUSSION
In this large prospective cohort study of consecutive primary
NMSCs with excellent long-term follow-up, at least 95%
of tumors were cured. Rates of tumor recurrence were
similar after different treatments, even after adjustment for
conventional risk factors in patients, tumors, or care. Destruc-
tion is recommended only for tumors at low risk for recurrence
and those in cosmetically less important body locations
(NCCN, 2011), but in the tumors treated with excision or
Mohs surgery the hazard of recurrence was not significantly
different, even in analyses adjusted for propensity for
treatment with Mohs surgery.
Comparison with past studies
Precise NMSC recurrence rates have not been known (Bath-
Hextall et al., 2004). Automated data sets usually have
insufficient information, and comprehensive follow-up
requires direct review of outpatient medical records
(including progress notes, photographs, diagrams, and
dermatopathology records) by experienced clinicians who
are blinded to treatment type. Many previous studies have
not followed patients for at least 5 years (Smeets et al., 2004),
nor adjusted for risk factors or differential follow-up using
survival analysis techniques.
The recurrence rate after destruction (4.9%) was lower than
expected, but the similarity of recurrence rates after excision
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Figure 2. Cumulative incidence of recurrence at the university site, Veterans Affairs Medical Center (VA) site, and the entire sample. (a) Cumulative incidence
of recurrence among 667 patients with 857 nonmelanoma skin cancers (NMSCs) at the university site. No statistically significant difference (P¼ 0.09)
detected in tumors treated with destruction, excision, or Mohs surgery. (b). Cumulative incidence of recurrence among 507 patients with 631 NMSCs at the
VA site. No statistically significant difference (P¼ 0.56) detected in tumors treated with destruction, excision, or Mohs surgery. (c) Cumulative incidence
of recurrence among 1,174 patients with 1,488 NMSCs in the entire sample. No statistically significant difference (P¼0.26) detected in tumors treated with
destruction, excision, or Mohs surgery.
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Table 2. Mean NMSC recurrence rates 5 years after treatment in clinical subgroups
Recurrence rate (95% CI)1
Characteristic University site (n¼857) VA site (n¼631) Entire sample (n¼ 1,488)
Patient characteristics
Age, years
omedian of 69 years 3.8% (1.9, 5.7) 4.2% (1.3, 7.0) 3.9% (2.3, 5.5)
Xmedian of 69 years 2.4% (0.5, 4.4) 2.8% (1.0, 4.7) 2.7% (1.3, 4.0)
Gender
Female 3.2% (1.0, 5.3) 0.0% (0.0, 20.6) 3.0% (0.9, 5.0)
Male 3.4% (1.5, 5.2) 3.5% (1.9, 5.2) 3.5% (2.2, 4.7)
Skin type (Fitzpatrick, 1988)
Type I or II 4.4% (1.2, 7.6) 3.9% (0.5, 7.3) 4.2% (1.8, 6.5)
Type III–VI 3.5% (0.9, 6.0) 3.5% (1.1, 5.9) 3.5% (1.7, 5.2)
Health Status (SF-12)
Physical component score
omedian of 48.7 5.3% (1.4, 9.2) 2.3% (0.3, 4.4) 3.5% (1.5, 5.4)
Xmedian of 48.7 2.8% (0.6, 5.0) 4.4% (0.5, 8.1) 3.4% (1.4, 5.3)
Mental component score
omedian of 51.5 3.4% (0.4, 6.2) 5.3% (1.6, 8.9) 4.3% (2.0, 6.6)
Xmedian of 51.5 4.2% (1.3, 7.0) 1.1% (0, 2.6) 2.7% (1.0, 4.4)
Comorbidity (Charlson index)
omedian of 1 2.4% (0.0, 4.7) 6.1% (1.2, 10.7) 3.8% (1.4, 6.0)
Xmedian of 1 5.0% (1.9, 8.1) 2.5% (0.6, 4.4) 3.6% (1.9, 5.2)
History of prior NMSC
No history 2.0% (0.4, 3.6)2 2.6% (0.3, 4.8) 2.3% (0.9, 3.6)3
History 4.5% (2.2, 6.8) 4.0% (1.7, 6.2) 4.3% (2.7, 5.8)
History of organ transplantation
No history 3.4% (2.0, 4.9) 3.5% (1.8, 5.2) 3.5% (2.4, 4.6)
History 0.0% (0.0, 12.8) 0.0% (0.0, 23.2) 0.0% (0.0, 8.6)
History of HIV
No history 2.5% (1.2, 3.8)4 3.1% (1.5, 4.6)4 2.8% (1.8, 3.7)4
History 19.6% (4.0, 32.7) 27.1% (0.0, 53.2) 20.8% (6.6, 32.9)
Number of NMSCs at presentation
pmedian of 1 1.9% (0.6, 3.3)4 2.0% (0.5, 3.4) 2.0% (1.0, 2.9)4
4median of 1 5.8% (2.7, 8.9) 5.9% (2.2, 9.4) 5.9% (3.5, 8.2)
Tumor characteristics n¼857 n¼ 631 n¼ 1488
Histological type
BCC 3.3% (1.7, 4.8) 3.5% (1.6, 5.4) 3.4% (2.1, 4.6)
SCC 3.3% (0.4, 6.2) 3.1% (0.0, 6.0) 3.2% (1.1, 5.2)
High-risk histological features (NCCN, 2011)
No high-risk features 3.9% (2.2, 5.7) 3.6% (1.8, 5.5) 3.8% (2.5, 5.0)
High-risk features 1.2% (0.0, 2.9) 2.3% (0.0, 5.4) 1.6% (0.0, 3.1)
Tumor diameter, mm
omedian of 8 mm 4.0% (1.5, 6.3) 2.8% (0.3, 5.3) 3.5% (1.7, 5.3)
Xmedian of 8 mm 2.7% (0.8, 4.6) 3.3% (1.0, 5.5) 3.0% (1.5, 4.4)
Tumor present in the ‘‘H-zone’’ of the face
Not present 3.7% (1.9, 5.4) 3.0% (1.0, 5.0) 3.4% (2.1, 4.8)
Table 2 continued on following page
M-M Chren et al.
Recurrence of Nonmelanoma Skin Cancer
1192 Journal of Investigative Dermatology (2013) Volume 133
and Mohs surgery is consistent with the findings of a
randomized controlled trial of the treatments for facial BCCs
(Mosterd et al., 2008). Our results expand previous findings, as
we prospectively enrolled a large consecutive sample at two
sites, adjusted for risk factors and follow-up, and studied
5-year outcomes in practice.
We have previously described recurrence outcomes only
at the VA site (Chren et al., 2011) because the electronic
records there were more feasible to obtain. However, the
sample size prevented comparisons among treatments.
At both sites we found recurrence rates to be similarly
low in many conventional ‘‘high-risk’’ clinical subgroups
(NCCN, 2011). Of particular note is the unexplained high
recurrence rate in patients with HIV infection (Hausauer
et al., 2012); similar results were not found in patients
who had received organ transplantations, a group at high
Table 2. (Continued )
Recurrence rate (95% CI)1
Characteristic University site (n¼857) VA site (n¼631) Entire sample (n¼ 1,488)
Present 2.4% (0.3, 4.5) 4.0% (1.2, 6.6) 3.2% (1.5, 4.9)
Care characteristics
Training level of treating clinician
Attending physician 3.4% (1.9, 4.8) 2.2% (0.0, 4.6) 3.1% (1.8, 4.3)
Resident physician 0.0% (0.0, 9.3) 4.2% (1.9, 6.5) 3.8% (1.7, 5.8)
Nurse practitioner N.A. 4.2% (0.0, 11.8) N.A.
Treatment of NMSC
Destruction 6.2% (2.5, 9.6)3 2.8% (0.0, 6.0) 4.9% (2.3, 7.4)
Excision 2.6% (0.3, 4.9) 4.2% (1.7, 6.6) 3.5% (1.8, 5.2)
Mohs surgery 1.9% (0.2, 3.5) 2.4% (0.0, 5.1) 2.1% (0.6, 3.5)
Number of annual visits to dermatology
p2 visits 2.0% (0.7, 3.3)4 2.3% (0.3, 4.4) 2.1% (1.0, 3.2)4
42 visits 6.6% (2.8, 10.2) 4.3% (1.9, 6.7) 5.2% (3.1, 7.2)
Abbreviations: BCC, basal cell carcinoma; CI, confidence interval; N.A., not applicable; NMSC, nonmelanoma skin cancer; SCC, squamous cell carcinoma;
SF-12, Short Form-12; VA, Veterans Affairs Medical Center.
1P-values refer to comparisons of subgroups within each column.
20.01pPo0.05.
30.05pPp0.10.
4Po0.01.
Entries in bold type are significant at Pp0.10.
Table 3. NMSC recurrence rates 5 years after different treatments, in subgroups of tumors conventionally believed to
be high risk for recurrence
5-Year recurrence rates (95% CI)
University site VA site
Tumors at high risk for recurrence No. Destruction Excision Mohs surgery No. Destruction Excision Mohs surgery
SCC 189 4.9% (0, 11.4) 6.1% (0, 12.5) 0% (0, 4.0) 177 0% (0, 8.5) 3.1% (0, 6.5) 4% (0, 11.4)
Diameter X20 mm 211 15.4% (1.9, 27.0) 0% (0, 7.4) 1.6% (0, 4.6) 198 0% (0, 16.1) 3.7% (0, 7.3) 0% (0, 10.3)
Invasive histologically 577 5.1% (0, 10.5) 1.4% (0, 3.2) 2.2% (0.3, 4.1)1 499 4.6% (0, 9.7) 3.6% (1.1, 6.1) 1.8% (0, 4.3)
Located in H-zone of face
(Swanson et al., 1983)
269 9.5% (0, 25.6) 6.3% (0, 14.5) 1.2% (0, 2.8)2 275 0% (0.0, 19.5) 5.8% (0.7, 10.7) 3% (0, 6.3)
High-risk location and size
(NCCN, 2011)3
185 0% (0.0, 41.0) 7.0% (0, 15.9) 0% (0.0, 3.4) 175 0% (0, 36.9) 4.8% (0, 10.0) 3.2% (0, 7.5)
Abbreviations: CI, confidence interval; NMSC, nonmelanoma skin cancer.
1P¼0.04.
2P¼0.05.
3Tumor located in H-zone of face or hand or genitals; size X6 mm.
Entries in bold type are significant at Pp0.05.
M-M Chren et al.
Recurrence of Nonmelanoma Skin Cancer
www.jidonline.org 1193
risk for primary NMSCs (Euvrard et al., 2003). Finally,
recurrence was more common in patients who visited the
dermatologist more often, which highlights the importance of
adjustments for surveillance bias.
Potential limitations
Although we studied care at two hospitals, the clinicians were
from a single dermatology department, which may limit
generalizability.
Treatment groups differed substantially and, although pro-
pensity-adjusted analyses failed to detect a difference in
recurrence rates, this study was not a randomized trial of
treatments. Unmeasured characteristics may have affected the
risk of recurrence.
Some patients may have received care at other sites and, if
so, actual recurrence rates may be higher. Over 80% of
patients had had a skin examination at the study sites in the
year before their final follow-up date, however, indicating that
the vast majority continued to receive follow-up dermatologic
care that we could review.
The minimum important difference in recurrence rates
between therapies has not been established (Shuster, 1999),
although some have acknowledged that a difference in
recurrence rates of 4% might be considered clinically
unimportant (McGovern and Leffell, 1999). We detected a
difference between excision and Mohs surgery of 1.4%
(0.5, 3.5) and suggest that as the confidence limits
exclude 4%, our results indicate that the treatments did not
differ significantly in preventing recurrence in our practice
settings. The overall sample may have been too small to
permit detection of differences in select subgroups. For
example, in unadjusted analyses at the university site,
recurrence was lower after Mohs surgery than excision for
tumors located in the H-zone of the face (1.2 vs. 6.3%,
P¼0.05; Table 3).
Treatment patterns may have changed since this cohort was
assembled. Topical agents are now used to treat some
histologically superficial NMSCs. However, even when these
tumors were eliminated we found similar recurrence rates
(Table 3). In addition, the use of Mohs surgery doubled in the
United States from 2001 to 2006 (Viola et al., 2012), which
suggests that the availability of and/or accepted indications for
Mohs surgery are changing (Shuster, 1999). If Mohs surgery
was used for subgroups of NMSCs other than those in which
its efficacy was originally described, then our ability to detect
its effectiveness in the overall cohort is lessened.
Outcomes other than recurrence are important, particularly
for nonfatal tumors (Feldman et al., 2008; Tinetti and Studenski,
2011). We have previously shown, however, that improvements
in tumor-related quality of life (bother from the treatment site,
including its appearance) were worse after destruction and
similar after excision and Mohs surgery (Chren et al., 2007).
Thus, for both clinical and patient-reported outcomes, surgical
excision and Mohs surgery led to similar outcomes.
Conclusions
Tumor recurrence was low after common treatments for
NMSC. Recurrence rates were similar after excision or Mohs
surgery, even after adjustment for conventional risk factors for
recurrence. These results from routine clinical care demon-
strate that future studies are needed to guide therapeutic
choices for different clinical subgroups.
MATERIALS AND METHODS
Design, setting, patients, and baseline data
We conducted a prospective cohort study of all patients with NMSC
diagnosed in 1999–2000, and treated in a university-based dermatol-
ogy practice or the dermatology clinic of the nearby affiliated VA. This
study was approved by the Institutional Review Boards and, when
required, patients provided written informed consent. The investigation
was conducted according to the Declaration of Helsinki Principles.
Details about the study have been described (Chren et al., 2004,
2011). Eligible patients were those with primary NMSC, defined histo-
pathologically as BCC, or SCC of the skin. We restricted the sample to
tumors treated with the three most common therapies: destruction with
electrodessication and curettage, excision, or Mohs surgery.
Most care at the university site was provided by attending
dermatologists. Most care at the VA, except Mohs surgery, was provi-
ded by dermatology residents supervised by attending physicians.
Dermatologic nurse practitioners provided a minority of care at the VA.
Table 4. Hazard of recurrence after treatment in NMSCs treated with Mohs surgery compared with excision
Hazard ratio (95% CI)
Sample of tumors treated with excision or Mohs surgery
Unadjusted Adjusted2 Propensity-adjusted3 Propensity-matched pairs1
University site 0.66 (0.24, 1.83) 1.07 (0.37, 3.10) 0.85 (0.30, 2.42) 0.70 (0.24, 2.08)
VA site 0.76 (0.30, 1.94) 0.44 (0.17, 1.19) 0.52 (0.21, 1.25) 0.65 (0.24, 1.76)
Full sample 0.65 (0.33, 1.27) 0.65 (0.32, 1.33) 0.62 (0.33, 1.20) 0.61 (0.30, 1.24)
Abbreviations: BCC, basal cell carcinoma; CI, confidence interval; NMSC, nonmelanoma skin cancer; SCC, squamous cell carcinoma; VA, Veterans Affairs
Medical Center.
1Subsample of tumors matched on propensity score; 240 pairs at the university site, 162 pairs at the VA site, and 402 pairs at both sites. All models adjusted for
42 annual visits to dermatology, and in the entire sample, clinical site.
2All models adjusted for history of HIV, multiple NMSCs at presentation, tumor in H-zone of the face, tumor type (BCC vs. SCC), whether the tumor was
histopathologically superficial or in situ, 42 annual visits to dermatology, and in the entire sample, clinical site.
3Adjusted by quintile of propensity score for performance of Mohs surgery for each tumor,42 annual visits to dermatology, and in the entire sample, clinical site.
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Excisions and Mohs surgery were usually carried out in specifically
designated clinics. Mohs surgery at both sites was typically performed
by a Mohs surgeon who was a member of the American College of
Mohs Micrographic Surgery and Cutaneous Oncology.
For destruction, usually three cycles of electrodessication/curettage
were carried out. Most excisions were simple excisions, and margins
of excised specimens were typically examined histologically in fixed
specimens after closure (Do, 2009).
Collection of outcome data
The primary source of data on recurrence was the medical record. At
a median of 9.0 years after treatment, trained dermatologic nurse
practitioners who were blinded to treatment type reviewed all records
using structured dataforms. To supplement this review, patients who
consented were examined at a median of 8.6 years after treatment by a
dermatologist (MMC) blinded to treatment type. If any irregularity near
the treatment site was noted (the examiner commented on the presence
of scaling, papule, erythema, erosion, induration, or cyst-like lesion),
the patient was referred to his/her dermatologist for assessment.
For all tumors with evidence of recurrence, the entire record was
reviewed again by an additional dermatologic clinician blinded to
details from the original review, to validate the outcome.
Measures
Primary outcome. A tumor was defined as recurrent if the tumor
type (BCC or SCC) and body location were identical to those of
the primary tumor, and the lesion was described by the clinician
as recurrent or previously treated. A tumor was defined as
probably recurrent if the tumor type was the same as that of the
primary tumor, and either (i) the body location of the suspected
lesion was very close to that of the primary tumor (e.g., ‘‘distal tip
of left nasal ala’’) or (ii) the body location of the suspected lesion
may have been the same as that of the primary tumor (e.g., ‘‘right
temple’’), and the lesion was described by the clinician as
recurrent or previously treated. A tumor was defined as of
uncertain recurrence if a suspicious lesion was noted on exam-
ination by the study dermatologist, but there was no subsequent
clinician evaluation. The date of recurrence was the date of
biopsy of the recurrent lesion.
Additional variables. Health status was measured with the Short
Form-12 instrument (Ware et al., 1996), comorbidity by an
adapted Charlson instrument (Charlson et al., 1987; Katz et al.,
1996), and photosensitivity (skin type) by an item about sunburn
and tanning (Fitzpatrick, 1988). History of prior NMSC, organ
transplantation, and infection with HIV was obtained from the
medical record. Tumors were classified according to the presence
of histological risk factors for recurrence (NCCN, 2011); facial
tumors were categorized by location in the H-zone of the face, an
area believed at higher risk for recurrence (Swanson et al., 1983).
We also counted each patient’s visits to dermatology throughout
follow-up.For each tumor, follow-up ended at the last date when
the patient received care. A patient was lost to follow-up if there
was no record of care after treatment.
Analytic strategy
Statistical analyses were performed using R version 2.13 (http://
www.R-project.org/). We defined recurrent tumors as those classified
as recurrent or probably recurrent. Analyses were repeated with two
alternative classifications: (i) recurrent tumors were only those
classified as recurrent, and (ii) recurrent tumors were those classified
as recurrent, probably recurrent, or uncertain. The conclusions were
not substantively different with the alternative classifications, and are
not reported. Because of differences in patients and tumors at the two
clinical sites, we performed both site-stratified and combined analyses.
Where results are reported in the entire sample, the conclusions did not
differ at the two clinical sites, except as noted.
We compared treatment groups using w2-tests for categorical
characteristics, and nonparametric analysis of variance (Kruskal–
Wallis test) for continuous characteristics. The Huber–White method
was used to adjust for patients with more than one tumor. Cumulative
incidence of tumor recurrence over time was displayed using Kaplan–
Meier plots. Data were right-censored on the last date of care. We
determined unadjusted 5-year recurrence rates in the entire sample, in
important clinical subgroups, and after each treatment in subgroups of
tumors conventionally believed to be a high risk for recurrence, using
the Kaplan–Meier method. The high-risk subgroups were tumors that
were X20 mm in diameter, invasive histologically, located in the
H-zone of the face (Swanson et al., 1983), or considered high risk by
location and size (NCCN, 2011). Exact binomial confidence intervals
were used in cases where the recurrence rate was 0%.
We next performed a series of Cox proportional hazard models to
calculate 5-year recurrence rates and hazard ratios, after adjustment
for characteristics likely related to recurrence. The R function cox.zph
(http://CRAN.R-project.org/package=survival) was applied on all mul-
tivariate models to confirm that the proportionality assumption was
met. Models were developed in the tumors treated with excision or
Mohs surgery, because destruction is recommended only for low-risk
tumors (NCCN, 2011), and those treated with destruction were
different in many respects from the other tumors. First, we fit a
large model with all potential predictors of recurrence. These
variables included age, gender, history of prior NMSC, infection
with HIV, multiple NMSCs (41) at study presentation, tumor type
(BCC vs. SCC), whether the tumor was histopathologically superficial
or in situ, the presence of histological risk factors for recurrence
(NCCN, 2011), tumor location in the H-zone of the face (Swanson
et al., 1983), tumor diameter 410 mm, and 42 annual dermatology
visits. Because of the limited number of recurrences, we also obtained
a more parsimonious set of independent variables by forcing treatment
type and tumor type into the model with all the potential variables
listed above, and applying a forward stepwise selection based on the
Akaike Information Criterion. The results from both sets of models were
similar, and only results from the parsimonious models are presented.
We also applied propensity score methods to adjust for measured
differences between patients and tumors that might relate to the
choice between Mohs surgery and excision (Rubin, 1997;
D’Agostino, 1998). At each clinical site, a propensity score for
Mohs surgery was calculated for each tumor, using a logistic
regression model for the performance of Mohs surgery. The model
included age, gender, infection with HIV, history of prior NMSC,
multiple NMSCs at presentation, tumor type, whether the tumor was
histopathologically superficial or in situ, the presence of
histopathological risk factors for recurrence (NCCN, 2011), tumor
location in the H-zone of the face (Swanson et al., 1983), and
whether the treatment choice was made by an attending physician,
resident physician, or nurse practitioner. We then used quintiles of
propensity as independent variables in Cox regression analyses of
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recurrence. We also modeled recurrence in subsamples of pairs of
tumors matched on propensity score, using the R function match in
the Matching package (Jasjeet, 2011).
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